Discussion on the probability of t790m mutation after resistance to dacomitinib/dacomitinib

Dacomitinib, also known as dacomitinib (Dacomitinib), is an oral drug approved by the U.S. Food and Drug Administration (FDA). It is an irreversible pan-human epidermal growth factor receptor tyrosine kinase inhibitor (TKI). This drug is mainly used to treat metastatic non-small cell lung cancer (NSCLC), especially cases with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutation.

Unfortunately, similar to otherEGFR-TKIs, dacomitinib may also encounter resistance problems during the treatment process. Among them, T790M mutation is a major mechanism causing EGFR drug resistance. Specifically, the T790M mutation involves the replacement of thymine (T) by methionine (M) at position 790 on the EGFR gene. This change will change the structure of the EGFR protein, thereby affecting its binding to TKI drugs, ultimately leading to the weakening or failure of TKI drugs to inhibit EGFR. Therefore, the T790M mutation is seen as a key factor leading to dacomitinib resistance.

When talking about the probability of T790M mutation after dacomitinib resistanceThis is actually a complex issue affected by multiple factors. The patient's genetic background, type of tumor, disease stage, and EGFR mutation status before treatment will all affect the probability of T790M mutation after drug resistance. In addition, the dosage of drugs used in treatment, the duration of treatment, and whether it is used in combination with other drugs may also play a role in the formation of drug resistance mechanisms.

It is worth noting that althoughT790M mutation is an important cause of dacomitinib resistance, not all drug-resistant patients will have this mutation. Therefore, when patients develop drug resistance, it is necessary to determine the specific drug resistance mechanism through genetic testing and other means in order to formulate more effective treatment plans.